Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Direct oral anticoagulants (DOACs) are a new class of anticoagulants that directly inhibit either thrombin or factor Xa in the coagulation cascade. They are being increasingly used instead of warfarin or other vitamin K antagonists (VKAs). Adverse side effects of DOACs may result in hemorrhagic complications, including life-threatening intracranial hemorrhage (ICH), though to a much lesser degree than VKAs. Currently there are relatively limited indications for DOACS but their usage is certain to expand with the availability of their respective specific reversal agents. Currently, only idarucizumab (antidote for dabigatran) has been United States Food and Drug Administration- (FDA-) approved, but others (andexanet-α and ciraparantag) may be approved in near future, and the development and availability of such reversal agents have the potential to dramatically change the current anticoagulant use by providing reversal of multiple oral anticoagulants. Until all the DOACs have FDA-approved reversal agents, the treatment of the dreaded side effects of bleeding is challenging. This article is an attempt to provide an overview of the management of hemorrhage, especially ICH, related to DOAC use.

Original languageEnglish (US)
Article number4907164
JournalCritical Care Research and Practice
Volume2018
DOIs
StatePublished - Jan 1 2018

Fingerprint

Intracranial Hemorrhages
Anticoagulants
Vitamin K
United States Food and Drug Administration
Hemorrhage
Antidotes
Factor Xa
Warfarin
Thrombin

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

@article{9942cb182ba541f4a0036a5913bfc634,
title = "Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications",
abstract = "Direct oral anticoagulants (DOACs) are a new class of anticoagulants that directly inhibit either thrombin or factor Xa in the coagulation cascade. They are being increasingly used instead of warfarin or other vitamin K antagonists (VKAs). Adverse side effects of DOACs may result in hemorrhagic complications, including life-threatening intracranial hemorrhage (ICH), though to a much lesser degree than VKAs. Currently there are relatively limited indications for DOACS but their usage is certain to expand with the availability of their respective specific reversal agents. Currently, only idarucizumab (antidote for dabigatran) has been United States Food and Drug Administration- (FDA-) approved, but others (andexanet-α and ciraparantag) may be approved in near future, and the development and availability of such reversal agents have the potential to dramatically change the current anticoagulant use by providing reversal of multiple oral anticoagulants. Until all the DOACs have FDA-approved reversal agents, the treatment of the dreaded side effects of bleeding is challenging. This article is an attempt to provide an overview of the management of hemorrhage, especially ICH, related to DOAC use.",
author = "Alok Dabi and Aristides Koutrouvelis",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/4907164",
language = "English (US)",
volume = "2018",
journal = "Critical Care Research and Practice",
issn = "2090-1305",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications

AU - Dabi, Alok

AU - Koutrouvelis, Aristides

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Direct oral anticoagulants (DOACs) are a new class of anticoagulants that directly inhibit either thrombin or factor Xa in the coagulation cascade. They are being increasingly used instead of warfarin or other vitamin K antagonists (VKAs). Adverse side effects of DOACs may result in hemorrhagic complications, including life-threatening intracranial hemorrhage (ICH), though to a much lesser degree than VKAs. Currently there are relatively limited indications for DOACS but their usage is certain to expand with the availability of their respective specific reversal agents. Currently, only idarucizumab (antidote for dabigatran) has been United States Food and Drug Administration- (FDA-) approved, but others (andexanet-α and ciraparantag) may be approved in near future, and the development and availability of such reversal agents have the potential to dramatically change the current anticoagulant use by providing reversal of multiple oral anticoagulants. Until all the DOACs have FDA-approved reversal agents, the treatment of the dreaded side effects of bleeding is challenging. This article is an attempt to provide an overview of the management of hemorrhage, especially ICH, related to DOAC use.

AB - Direct oral anticoagulants (DOACs) are a new class of anticoagulants that directly inhibit either thrombin or factor Xa in the coagulation cascade. They are being increasingly used instead of warfarin or other vitamin K antagonists (VKAs). Adverse side effects of DOACs may result in hemorrhagic complications, including life-threatening intracranial hemorrhage (ICH), though to a much lesser degree than VKAs. Currently there are relatively limited indications for DOACS but their usage is certain to expand with the availability of their respective specific reversal agents. Currently, only idarucizumab (antidote for dabigatran) has been United States Food and Drug Administration- (FDA-) approved, but others (andexanet-α and ciraparantag) may be approved in near future, and the development and availability of such reversal agents have the potential to dramatically change the current anticoagulant use by providing reversal of multiple oral anticoagulants. Until all the DOACs have FDA-approved reversal agents, the treatment of the dreaded side effects of bleeding is challenging. This article is an attempt to provide an overview of the management of hemorrhage, especially ICH, related to DOAC use.

UR - http://www.scopus.com/inward/record.url?scp=85050212715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050212715&partnerID=8YFLogxK

U2 - 10.1155/2018/4907164

DO - 10.1155/2018/4907164

M3 - Review article

VL - 2018

JO - Critical Care Research and Practice

JF - Critical Care Research and Practice

SN - 2090-1305

M1 - 4907164

ER -